Independent register of U.S. FDA drug recalls · updated Oct 10, 2026
RxRecalls Get alerts
Class II · Moderate risk Ongoing Initiated Apr 26, 2023 (3 years ago)

Midazolam Injection

Class II — Moderate risk. May cause temporary or reversible harm; serious harm unlikely.

Why it was recalled

CGMP Deviations: Firm went out of business and could no longer continue stability studies.

Cause type: Stability / shelf life

The product degraded or failed stability testing before its labeled expiry. Heat, moisture or time can break the drug down into degradants or reduce potency. All stability / shelf life recalls.

What was recalled

Midazolam Injection, USP, 50 mg/10mL (5mg/mL), For Intramuscular or Intravenous Use Only, 10 mL vials, Rx Only, Manufactured by: Akorn, Inc., Lake Forest, IL 60045. ALL NDCs

Drug: Midazolam

Recalling firm
Akorn, Inc.
Origin
IL, United States
Initiated by
Voluntary: Firm initiated
FDA recall number
D-0859-2023 · FDA notice

Check, then ask. Class II means harm is possible but usually temporary or reversible. Find the lot number on your package; if it matches, ask your pharmacist about a replacement. Do not simply stop a prescribed medication on your own - the gap can be riskier than the recall.

Other Midazolam recalls

See all
Class II · Moderate risk

midazolam in dextrose 5%

Lack of assurance of sterility: Lack of validation data for sanitization cycles

Terminated Sterility / contamination Central Admixture Pharmacy Services Inc NDC 71286-4036-1 D-1075-2023
Class II · Moderate risk

Midazolam Injection

CGMP Deviations: Firm went out of business and could no longer continue stability studies.

Ongoing Stability / shelf life Akorn, Inc. D-0828-2023

Other recalls by Akorn, Inc.

All 2023 recalls